738 results about "Therapeutic treatment" patented technology

A method and apparatus are provided for performing a therapeutic treatment on a patient's skin by concentrating applied radiation of at least one selected wavelength at a plurality of selected, three-dimensionally located, treatment portions, which treatment portions are within non-treatment portions. The ratio of treatment portions to the total volume may vary from 0.1% to 90%, but is preferably less than 50%. Various techniques, including wavelength, may be utilized to control the depth to which radiation is concentrated and suitable optical systems may be provided to concentrate applied radiation in parallel or in series for selected combinations of one or more treatment portions.

This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.

Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.

A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation.

Disclosed are techniques for operation of neurostimulation or drug delivery devices to stop treatment therapy during times when the patient does not need to be treated. Advantageously, the present invention reduces battery usage and/or drug dosage during periods when treatment therapy need not be provided. Further, the present invention slows or reduces the tolerance the patient may develop from the electrical stimulation or treatment therapy. In one embodiment, the present invention includes a timer or a real time clock for shutting off the device during periods when the patient is sleeping in accordance with a preset schedule. The present invention preferably turns off after the patient has fallen asleep and right before the patient has awakened. Alternatively, the invention may include a sensor for sensing conditions indicative of whether the patient is awake or asleep. This sensed information may also be used to determine whether the treatment therapy should be delivered or stopped.

A method and apparatus is described for treating a target body surface using a radiation applicator. The therapeutic treatment apparatus adapted to conform to a patients body. The treatment apparatus comprises a plurality of light sources coupled with a flexible substrate, a light integrator in at least a portion of the optical path between the light source and the patient's body surface, a power supply, and a controller.

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.

Described are devices and methods for treating degenerative, congestive heart disease and related valvular dysfunction. Percutaneous and minimally invasive surgical tensioning structures offer devices that mitigate changes in the ventricular structure (i.e., remodeling) and deterioration of global left ventricular performance related to tissue damage precipitating from ischemia, acute myocardial infarction (AMI) or other abnormalities. These tensioning structures can be implanted within various major coronary blood-carrying conduit structures (arteries, veins and branching vessels), into or through myocardium, or into engagement with other anatomic structures that impact cardiac output to provide tensile support to the heart muscle wall which resists diastolic filling pressure while simultaneously providing a compressive force to the muscle wall to limit, compensate or provide therapeutic treatment for congestive heart failure and/or to reverse the remodeling that produces an enlarged heart.

This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.

A system and method for providing a therapeutic treatment, such as a flow of breathing gas, to a patient at variable treatment levels. A respiratory cycle monitor detects the patient's respiratory cycles and a control unit incrementally adjusts the treatment level from a first predetermined level to a second predetermined level over a first predetermined number of respiratory cycles. The amount of the incremental adjustment and the frequency of such adjustments over the course of the first predetermined number of respiratory cycles can be controlled to achieve a desired change in the therapeutic treatment over the course of the patient's respiration.

The invention provides a method for humanizing a rabbit monoclonal antibody. In general, the method involves comparing an amino acid sequences of a parent rabbit antibody to the amino acid sequences of a similar human antibody, and altering the amino acid sequence of the parent rabbit antibody such its framework regions are more similar in sequence to the equivalent framework regions of the similar human antibody. In many embodiments, amino acids in the parent rabbit antibody that are not CDR contact residues, interchain contact residues, or buried residues, are not modified. The invention further provides nucleic acids encoding the subject antibodies, as well as vectors and host cells comprising the nucleic acids and methods for producing a subject antibody. The subject antibodies, nucleic acid compositions and kits find use in a variety of applications, including diagnostics and therapeutic treatment and research of conditions and diseases.

There is provided a flexible guide tube which guides an endoscope or a therapeutic device into an abdominal cavity through the mouth and stomach to conduct an observation or a therapeutic treatment in the abdominal cavity. The guide tube includes an insertion section which has a distal end, a peripheral section, and a central axis, and which is capable of being inserted into a body through the mouth, and two expandable and shrinkable balloons arranged in the vicinity of the distal end at a predetermined distance from each other in the axial direction on the periphery of the insertion section. The predetermined distance is preferably set to 3 to 8 mm, and the length of the insertion section is preferably set to about 600 to 1000 mm.

A non-invasive visual imaging system is provided, wherein the imaging system procures an image of a transducer position during diagnostic or therapeutic treatment. In addition, the system suitably provides for the transducer to capture patient information, such as acoustic, temperature, or ultrasonic images. For example, an ultrasonic image captured by the transducer can be correlated, fused or otherwise combined with the corresponding positional transducer image, such that the corresponding images represent not only the location of the transducer with respect to the patient, but also the ultrasonic image of the region of interest being scanned. Further, a system is provided wherein the information relating to the transducer position on a single patient may be used to capture similar imaging planes on the same patient, or with subsequent patients. Moreover, the imaging information can be effectively utilized as a training tool for medical practitioners.

An intervertebral spacer for therapeutic treatment of a patient includes at least one link sized and dimensioned to fit within an intervertebral space in the patient, and is configured to maintain a separation of two adjacent vertebrae for a period of time. A rigid guiding object, which may be a tool or a successive link, is insertable into the patient, to guide other links into the patient using an MIS approach. A pivot is connected between successive links, or between a guide tool and a link, configured to limit a relative range of angular orientation between the link and the guiding tool, or successive links. Multiple links are so joined to form a chain pushable by the last link, and pullable by the first link, to form a chain which may be formed into a curved configuration corresponding to the patient's intervertebral space.

Provided is an implantable RFID-enabled micro-electronic neurostimulator system comprising a) an internal subsystem having (i) an array of electrodes, where at least one electrode pair contacts a nerve; (ii) a multiplexer; (iii) digital to analog signal converter; and (iv) a RFID based control and stimulation chip; and (b) an external subsystem having (i) a controller; and (ii) an RF interface.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

An optimal transcranial or intracranial application of electrical energy for is determined for therapeutic treatment. MRI or CAT scan data, or both, are obtained for a subject brain. Different electrical resistance values are assigned to portions of the subject brain based on the data. Electrode sites are selected. Based on the assigning and selecting, one or more applied electrical inputs are calculated for optimal therapeutic application of transcranial or intracranial electricity.

A disposable electrical stimulation device and method for providing therapeutic treatment and pain management in a convenient, compact configuration. Electrode size and shape and relative configuration can be varied according to an intended application and use, or a universal configuration can be provided for use on almost any area of the body. The common structure of communicatively coupled dual electrodes including control circuitry and a power source accommodates a range of different sizes, configurations, stimulation treatment intensities, and other physical and electrical characteristics that can be pre-customized and packaged for specific, limited time use. The device can therefore be used in methods of providing therapy, managing pain, and achieving other treatment goals by electrical stimulation.

The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR Vβ region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.

A non-invasive visual imaging system is provided, wherein the imaging system procures an image of a transducer position during diagnostic or therapeutic treatment. In addition, the system suitably provides for the transducer to capture patient information, such as acoustic, temperature, or ultrasonic images. For example, an ultrasonic image captured by the transducer can be correlated, fused or otherwise combined with the corresponding positional transducer image, such that the corresponding images represent not only the location of the transducer with respect to the patient, but also the ultrasonic image of the region of interest being scanned. Further, a system is provided wherein the information relating to the transducer position on a single patient may be used to capture similar imaging planes on the same patient, or with subsequent patients. Moreover, the imaging information can be effectively utilized as a training tool for medical practitioners.

Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the alpha -hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one calcitonin gene related peptide ("CGRP") antagonist, e.g., CGRP 8-37 or an anti-CGRP antibody.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and/or to develop and monitor the outcome of therapeutic treatments. An exemplary disease/condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

Systems, methods and computer program products for guiding selection of a therapeutic treatment regimen or a preventive therapeutic treatment regimen are disclosed. The method comprises (A) providing to a computing device comprising a first knowledge base comprising information about a plurality of different methylation statuses at selected sites of the DNA in cells with a known disease or medical condition and/or healthy cells, a second knowledge base comprising a plurality of expert rules for evaluating and selecting a type of disease or medical condition based on the methylation status at selected sites of the DNA of a patient, (B) generating in said computing device a ranked listing of diseases or medical conditions based on the information about the methylation status at selected sites of the DNA of the patient, the first knowledge base and the second knowledge base.

This invention relates to a method of straddling an intraosseous nerve with an energy transmitting device to improve the therapeutic treatment of the nerve.

An apparatus for selectively positioning intraoral anatomic features of a human patient to enhance upper airway stability for use alone or in combination with positive airway pressure as therapeutic treatment for obstructive sleep apnea and other conditions, such as snoring, which are symptomatic of upper airway instability.

The present invention provides a handheld dermatological device for visualizing a skin treatment region prior to, during, or after therapeutic treatment with therapeutic energy. An apparatus according to the teachings of the invention can include an image capture device and a display device mounted to the apparatus and electrically coupled to the image capture device. The display device is capable of displaying images of the treatment area captured by the image capture device. The apparatus can further include a head capable of transmitting therapeutic energy to a treatment area, which can be precisely aligned by the user to a desired portion of the treatment area through the use of the display device. In some embodiments, the apparatus can include one or more illumination sources for illuminating a skin target region, and shield for shielding the image capture device from direct reflection of the illuminating radiation from a selected skin surface portion.

The invention relates to a device for performing and verifying therapeutic radiation. An x-ray beam (4) is arranged across from a target volume (3) of the beam source (11) for the high-energy beam (1) in such a way that the beams (1, 4) run in essentially opposite directions (5, 6). The invention also relates to a computer program and a control method for operating said device. The inventive device makes it possible to exactly verify areas (16, 16′, 16″) that are subjected to different levels of radiation, the entire anatomy of the target volume (3), and the surroundings thereof in addition to the contour of the therapy beam (1). The x-ray beam (4) detects the anatomy and position of the patient (21) within the range of the target volume (3) before the high-energy beam (1) is applied and the shape of the applied high-energy beam (1) is then detected and areas (16, 16′, 16″) that are subjected to different levels of radiation as well as at least one partial segment of the target volume (3) during the emission breaks of the high-energy beam (1). The detected data is used for correcting the treatment plan.

The method and apparatus of the invention are directed to surgically non-invasively treating skeleto/muscular injuries or of diagnosing bone fractures, involving application of two components of ultrasonic energy, to an external surface of living tissue, wherein the two components are of different frequencies in the range between 10 kHz and 4 MHz, and wherein separate transducers, each uniquely supplied with an excitation signal at a different one of the same two frequencies, are directionally disposed for acoustic propagation on the same directional axis.

Methods, systems and devices are described for Endobronchial Ventilation using an endobronchially implanted ventilator for the purpose of treating COPD, emphysema and other lung diseases. Endobronchial drug delivery is also described using an endobronchially implanted drug pump, for therapeutic treatment of the lung or of other organs and tissues.